Arthritis Drug Shows Promise for Treatment-Resistant Depression in Pilot Trial

A pilot clinical trial suggests that an immune-targeting arthritis medication may offer relief for people with depression that has not responded to standard treatments. Rather than targeting brain chemicals such as serotonin, the experimental approach focuses on reducing inflammation.

In the University of Bristol-led study, published on May 20 in JAMA Psychiatry, researchers evaluated tocilizumab in adults with moderate-to-severe treatment-resistant depression. All participants also had evidence of low-grade inflammation based on blood tests.

The Link Between Inflammation and Depression

Most antidepressants work by affecting neurotransmitters such as serotonin, dopamine, or norepinephrine. However, approximately one-third of patients experience little or no meaningful improvement, highlighting the need for alternative treatment approaches.

Growing evidence suggests that chronic inflammation and immune system activity contribute to depression in a subset of patients. Studies indicate that roughly one in three people with depression have elevated inflammatory markers, suggesting that immune pathways may influence mood, motivation, and energy levels.

One inflammatory molecule receiving particular attention is interleukin-6 (IL-6), which plays a central role in coordinating immune responses. Elevated IL-6 levels have repeatedly been linked to an increased risk of depression and more persistent symptoms.

Using a genetic research method known as Mendelian randomization, the University of Bristol team previously demonstrated that excessive IL-6 signaling may not simply be a consequence of depression. Their findings suggested that it could actively contribute to the development or persistence of depressive symptoms in some individuals.

Testing an Existing Arthritis Medication

To investigate this possibility, researchers conducted a four-week randomized, placebo-controlled clinical trial involving patients whose depression had not improved with conventional treatments. All participants had laboratory evidence of low-grade inflammation before enrollment.

Thirty volunteers were recruited through the University of Cambridge and the Cambridgeshire and Peterborough NHS Foundation Trust. Fourteen participants received a single infusion of tocilizumab, while sixteen received a placebo saline infusion.

Tocilizumab is an IL-6 receptor blocker widely used to treat rheumatoid arthritis and certain severe inflammatory conditions, including selected cases of COVID-19. By blocking IL-6 signaling, the medication reduces inflammatory activity throughout the body. Participants were monitored for four weeks to assess changes in depressive symptoms and overall well-being.

Because the study included only a small number of participants, its statistical power was limited, and several differences between the treatment and placebo groups did not reach conventional levels of statistical significance. Nevertheless, participants who received tocilizumab generally showed greater improvements across multiple clinical measures.

Compared with the placebo group, those treated with tocilizumab experienced larger reductions in depression severity, anxiety, and fatigue. They also reported greater improvements in overall quality of life.

By the end of the study, 54% of participants receiving tocilizumab met the criteria for remission, compared with 31% of those receiving placebo. This corresponded to a Number Needed to Treat (NNT) of five, meaning that one additional patient achieved remission for every five individuals treated.

For comparison, previous meta-analyses have estimated that selective serotonin reuptake inhibitors (SSRIs) typically have a Number Needed to Treat of approximately seven for moderate-to-severe depression. The researchers note that this comparison makes the early findings from immunotherapy particularly noteworthy, although much larger studies will be needed to confirm the results.

Moving Toward Personalized Depression Treatment

Golam Khandakar, Professor of Psychiatry and Immunology at the University of Bristol and senior author of the study, said the findings represent an encouraging step for patients with treatment-resistant depression, particularly those with evidence of inflammation.

The study is among the first randomized controlled trials to investigate immunotherapy for depression and the first to specifically target the IL-6 receptor. It is also distinctive because participants were selected based on biological evidence of inflammation rather than including people with depression regardless of inflammatory status.

Lead author Éimear Foley, Senior Research Associate in Immunopsychiatry, said the findings move the field closer to personalized treatment strategies. Matching therapies to an individual's underlying biology, she suggested, could improve outcomes while reducing the prolonged trial-and-error process that many patients experience with current antidepressants.

One study participant also emphasized the importance of volunteering for clinical research, noting that advances in medical treatment depend on people willing to participate in carefully conducted trials.

Next Steps and Remaining Questions

The researchers stress that these findings are preliminary and should not lead to routine off-label use of tocilizumab for depression. The medication can cause serious side effects, including an increased risk of infection, and it was not originally developed for psychiatric conditions.

The research team is now planning a larger Phase III randomized controlled trial to determine whether blocking IL-6 consistently produces meaningful and long-lasting improvements in depression. A larger study should also help identify which patients are most likely to benefit from this approach.

Future research will need to evaluate long-term safety, determine optimal dosing strategies, and clarify how immunotherapy might be combined with psychotherapy and conventional antidepressants. Cost-effectiveness and access will also be important considerations because biologic medications remain substantially more expensive than standard antidepressant treatments.

The study was funded by Wellcome, with additional support from the NIHR Biomedical Research Centres in Bristol and Cambridge and a BMA Foundation J. Moulton grant. If future trials confirm these early findings, immune-targeting therapies could become an important addition to the treatment options available for people with difficult-to-treat depression.